Literature DB >> 26437784

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.

M Ladetto1,2,3, S Ferrero1,2, D Drandi1,2, M Festuccia1,2, F Patriarca4, N Mordini5, S Cena1, R Benedetto1,2, G Guarona1,2, F Ferrando1, L Brunello1,2, P Ghione1,2, V Boccasavia1, R Fanin4, P Omedè1, L Giaccone1,2, A Palumbo1,2, R Passera6, M Boccadoro1,2, B Bruno1,2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26437784     DOI： 10.1038/leu.2015.269

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.

Authors:  Teresa Caballero-Velázquez; Lucia López-Corral; Cristina Encinas; Cristina Castilla-Llorente; Rodrigo Martino; Laura Rosiñol; Antonia Sampol; Dolores Caballero; David Serrano; Inmaculada Heras; Jesús San Miguel; José A Pérez-Simón
Journal:  Br J Haematol       Date:  2013-06-15       Impact factor: 6.998

2.  Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.

Authors:  Luisa Giaccone; Barry Storer; Francesca Patriarca; Marcello Rotta; Roberto Sorasio; Bernardino Allione; Fabrizio Carnevale-Schianca; Moreno Festuccia; Lucia Brunello; Paola Omedè; Sara Bringhen; Massimo Aglietta; Alessandro Levis; Nicola Mordini; Andrea Gallamini; Renato Fanin; Massimo Massaia; Antonio Palumbo; Giovannino Ciccone; Rainer Storb; Ted A Gooley; Mario Boccadoro; Benedetto Bruno
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

3.  Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma.

Authors:  M Ladetto; J W Donovan; S Harig; A Trojan; C Poor; R Schlossnan; K C Anderson; J G Gribben
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

Review 4.  Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.

Authors:  B Bruno; L Giaccone; M Rotta; K Anderson; M Boccadoro
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

Review 5.  Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.

Authors:  Moreno Festuccia; Massimo Martino; Federica Ferrando; Giuseppe Messina; Tiziana Moscato; Roberta Fedele; Mario Boccadoro; Luisa Giaccone; Benedetto Bruno
Journal:  Expert Opin Biol Ther       Date:  2015-04-12       Impact factor: 4.388

6.  Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

Authors:  Marco Ladetto; Gloria Pagliano; Simone Ferrero; Federica Cavallo; Daniela Drandi; Loredana Santo; Claudia Crippa; Luca De Rosa; Patrizia Pregno; Mariella Grasso; Anna Marina Liberati; Tommaso Caravita; Francesco Pisani; Tommasina Guglielmelli; Vincenzo Callea; Pellegrino Musto; Clotilde Cangialosi; Roberto Passera; Mario Boccadoro; Antonio Palumbo
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

7.  Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

Authors:  Paolo Corradini; Michele Cavo; Henk Lokhorst; Giovanni Martinelli; Carolina Terragna; Ignazio Majolino; Pinuccia Valagussa; Mario Boccadoro; Diana Samson; Andrea Bacigalupo; Nigel Russell; Vittorio Montefusco; Claudia Voena; Gosta Gahrton
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

8.  Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

Authors:  Nicolaus Kröger; Anita Badbaran; Tatjana Zabelina; Francis Ayuk; Christine Wolschke; Haefaa Alchalby; Evgeny Klyuchnikov; Djordje Atanackovic; Georgia Schilling; Timon Hansen; Sabine Schwarz; Marion Heinzelmann; Silke Zeschke; Ulrike Bacher; Thomas Stübig; Boris Fehse; Axel R Zander
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-16       Impact factor: 5.742

9.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

Authors:  V H J van der Velden; G Cazzaniga; A Schrauder; J Hancock; P Bader; E R Panzer-Grumayer; T Flohr; R Sutton; H Cave; H O Madsen; J M Cayuela; J Trka; C Eckert; L Foroni; U Zur Stadt; K Beldjord; T Raff; C E van der Schoot; J J M van Dongen
Journal:  Leukemia       Date:  2007-02-08       Impact factor: 11.528

10.  A comparison of allografting with autografting for newly diagnosed myeloma.

Authors:  Benedetto Bruno; Marcello Rotta; Francesca Patriarca; Nicola Mordini; Bernardino Allione; Fabrizio Carnevale-Schianca; Luisa Giaccone; Roberto Sorasio; Paola Omedè; Ileana Baldi; Sara Bringhen; Massimo Massaia; Massimo Aglietta; Alessandro Levis; Andrea Gallamini; Renato Fanin; Antonio Palumbo; Rainer Storb; Giovannino Ciccone; Mario Boccadoro
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245
View more
  15 in total

Review 1.  A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?

Authors:  Damian J Green; William I Bensinger
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 2.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.

Authors:  C Fernández de Larrea; J Dávila; I Isola; E M Ocio; L Rosiñol; R García-Sanz; M T Cibeira; N Tovar; M Rovira; M V Mateos; J S Miguel; J Bladé
Journal:  Bone Marrow Transplant       Date:  2016-11-21       Impact factor: 5.483

4.  The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?

Authors:  Antonia M S Müller; Shaji K Kumar; Benedetto Bruno
Journal:  Haematologica       Date:  2019-02       Impact factor: 9.941

5.  Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

Authors:  A P Nair; P Walker; A Kalff; K Bergin; J Hocking; S Avery; D J Curtis; S Patil; T Das; D Klarica; S Morgan; J Muirhead; M Gorniak; J Reynolds; A Spencer
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

6.  Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

Authors:  M Sobh; M Michallet; G Gahrton; S Iacobelli; A van Biezen; S Schönland; E Petersen; N Schaap; F Bonifazi; L Volin; E Meijer; D Niederwieser; J El Cheikh; R Tabrizi; N Fegeux; J Finke; D Bunjes; J Cornelissen; H Einsele; B Bruno; M Potter; R Fanin; M Mohty; L Garderet; N Kröger
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528

7.  Allogeneic transplantation for multiple myeloma: yes, no or maybe?

Authors:  B Bruno
Journal:  Bone Marrow Transplant       Date:  2016-02-22       Impact factor: 5.483

8.  Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.

Authors:  Hervé Avet-Loiseau; Heinz Ludwig; Ola Landgren; Bruno Paiva; Chris Morris; Hui Yang; Kefei Zhou; Sunhee Ro; Maria-Victoria Mateos
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-10-09

Review 9.  Methods and role of minimal residual disease after stem cell transplantation.

Authors:  Marco Ladetto; Sebastian Böttcher; Nicolaus Kröger; Michael A Pulsipher; Peter Bader
Journal:  Bone Marrow Transplant       Date:  2018-08-16       Impact factor: 5.483

Review 10.  From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

Authors:  Francesca Gay; Monika Engelhardt; Evangelos Terpos; Ralph Wäsch; Luisa Giaccone; Holger W Auner; Jo Caers; Martin Gramatzki; Niels van de Donk; Stefania Oliva; Elena Zamagni; Laurent Garderet; Christian Straka; Roman Hajek; Heinz Ludwig; Herman Einsele; Meletios Dimopoulos; Mario Boccadoro; Nicolaus Kröger; Michele Cavo; Hartmut Goldschmidt; Benedetto Bruno; Pieter Sonneveld
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.